Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 216
interventional 198
Observational 17
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Biological 183
Behavioral 3
Biological|placebo 3
Other 3
Drug 2
Biological|Drug 1
Biological|Other 1
Biological|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 37
China 17
NA 15
Philippines 14
Korea, Republic of 9
India 8
Japan 7
Thailand 7
Vietnam 7
Canada 4
Germany 4
Russian Federation 4
South Africa 4
Colombia|Costa Rica 3
Finland 3
France|Germany 3
United Kingdom 3
United States|Canada 3
Argentina 2
Australia|Canada|Czechia|Finland|Italy|Spain 2
Belgium 2
Dominican Republic|Finland 2
France 2
Guinea-Bissau 2
Mexico 2
Poland 2
Singapore 2
Taiwan 2
Turkey 2
United States|Puerto Rico 2
Argentina|Nicaragua 1
Australia 1
Belgium|Netherlands|Spain 1
Canada|France|Germany 1
Chile|Mexico 1
Denmark 1
Finland|Italy|Sweden 1
Finland|Sweden 1
France|Poland 1
Germany|Italy 1
Germany|Poland|Spain 1
Italy 1
Italy|Australia|Canada|Czechia|Finland|Spain 1
Kenya 1
Mali 1
Mexico|Peru 1
Nigeria 1
Norway 1
Norway|Sweden 1
Peru 1
Philippines|Thailand 1
Spain 1

Sites per Study

Site_count Study_Count
1 74
2 21
3 20
4 10
5 1
6 3
7 3
8 5
9 5
10 2
11 3
12 3
13 3
14 3
15 2
16 3
17 1
19 3
20 4
22 3
23 1
24 3
26 2
29 1
30 1
33 1
34 2
35 1
36 1
37 1
38 1
42 1
43 2
44 1
45 1
50 1
51 1
58 1
63 1
64 1
72 1

Phase

Phase Study_Count
Phase 3 106
Phase 4 46
Phase 2 28
N/A 8
Phase 1 8
Phase 1/Phase 2 2

Number of Arms

Number_of_Arms Count_of_Studies
1 31
2 87
3 35
4 13
5 1
6 2
8 2
10 2
18 1
NA 24

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 46.00 30.000 43 5.0000 30.0000 55.0000
1st Qu. 224.25 40.750 373 268.0000 300.5000 212.7500
Median 1990.00 61.000 703 402.0000 490.0000 441.5000
Mean 10183.38 169.125 703 418.9643 742.3208 769.2391
3rd Qu. 4902.00 325.000 1033 525.0000 935.7500 748.7500
Max. 67000.00 420.000 1363 882.0000 4209.0000 6534.0000

Trial Group Type

group_type Group_Count
Experimental 294
Active Comparator 130
NA 24
No Intervention 6
Placebo Comparator 2
Other 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 156
Single Group Assignment 36
Crossover Assignment 4
Factorial Assignment 1
Sequential Assignment 1

Primary Purpose

primary_purpose Study_Count
Prevention 191
Treatment 2
NA 2
Basic Science 1
Diagnostic 1
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 4
Korea, Republic of 3
NA 3
Canada 2
Brazil 1
Colombia 1
South Africa 1
Spain 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 13
2 2
22 1
59 1

Enrollment Metrics

Measure Observational
Min 1.00
1st Qu 455.00
Median 1258.00
Mean 42545.59
3rd Qu 7156.00
Max 510000.00

Observation Model

observational_model Study_Count
Cohort 11
NA 3
Case Control 1
Ecologic or Community 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 9
Retrospective 4
Cross-Sectional 2
NA 2

Registries

Studies by Country

Country Study_Count
Israel 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 40
1st Qu 40
Median 40
Mean 40
3rd Qu 40
Max 40

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
4 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03589768 Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants https://ClinicalTrials.gov/show/NCT03589768 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-07-01
NCT03824093 High and Low Resource Interventions to Promote HPV Vaccines https://ClinicalTrials.gov/show/NCT03824093 Enrolling by invitation Children’s Mercy Hospital Kansas City 2019-12-31
NCT03311659 Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals’ Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects https://ClinicalTrials.gov/show/NCT03311659 Completed GlaxoSmithKline 2018-08-31
NCT02907216 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals’ Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants https://ClinicalTrials.gov/show/NCT02907216 Completed GlaxoSmithKline 2017-05-29
NCT02858440 A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia https://ClinicalTrials.gov/show/NCT02858440 Completed GlaxoSmithKline 2017-10-24
NCT02853929 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexaâ„¢ in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery https://ClinicalTrials.gov/show/NCT02853929 Completed GlaxoSmithKline 2019-03-19
NCT02817451 DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants https://ClinicalTrials.gov/show/NCT02817451 Completed Sanofi 2019-02-22
NCT02673255 Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program https://ClinicalTrials.gov/show/NCT02673255 Completed Biomat USA, Inc. 2019-07-29
NCT02640404 Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam https://ClinicalTrials.gov/show/NCT02640404 Completed Sanofi 2016-12-05
NCT02587520 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects https://ClinicalTrials.gov/show/NCT02587520 Completed Sanofi 2017-02-21
NCT02428491 Immunogenicity and Safety of Sanofi Pasteur’s Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth https://ClinicalTrials.gov/show/NCT02428491 Completed Sanofi 2017-01-11
NCT02422264 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery https://ClinicalTrials.gov/show/NCT02422264 Completed GlaxoSmithKline 2018-03-07
NCT02377349 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Pregnant Women https://ClinicalTrials.gov/show/NCT02377349 Completed GlaxoSmithKline 2017-08-14
NCT02274285 DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants https://ClinicalTrials.gov/show/NCT02274285 Completed Sanofi 2016-05-28
NCT02118961 Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents https://ClinicalTrials.gov/show/NCT02118961 Completed Mitsubishi Tanabe Pharma Corporation 2014-08-31
NCT02096263 Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants https://ClinicalTrials.gov/show/NCT02096263 Completed GlaxoSmithKline 2015-02-06
NCT02094833 DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants https://ClinicalTrials.gov/show/NCT02094833 Completed Sanofi 2016-04-30
NCT02089347 Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old https://ClinicalTrials.gov/show/NCT02089347 Completed Sanofi 2014-09-30
NCT01311557 Study of Adacel® Vaccine Administered to Persons 10 Years of Age https://ClinicalTrials.gov/show/NCT01311557 Completed Sanofi 2011-11-30
NCT01309646 Immunogenicity and Safety of GlaxoSmithKline Biologicals’ Infanrixâ„¢-IPV+Hib Vaccine https://ClinicalTrials.gov/show/NCT01309646 Completed GlaxoSmithKline 2012-02-24
NCT01294605 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) https://ClinicalTrials.gov/show/NCT01294605 Completed GlaxoSmithKline 2004-09-30
NCT01287949 Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older https://ClinicalTrials.gov/show/NCT01287949 Completed Sanofi 2012-05-31
NCT01277705 Comparison of GSK Biologicals’ Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® https://ClinicalTrials.gov/show/NCT01277705 Completed GlaxoSmithKline 2002-04-30
NCT02040636 Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis https://ClinicalTrials.gov/show/NCT02040636 Completed Sanofi 2000-05-31
NCT01993173 Sanofi Pasteur’s Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. https://ClinicalTrials.gov/show/NCT01993173 Completed Sanofi 2014-02-28
NCT01988857 Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Healthy Vietnamese Children https://ClinicalTrials.gov/show/NCT01988857 Completed GlaxoSmithKline 2014-05-10
NCT01983540 Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination https://ClinicalTrials.gov/show/NCT01983540 Completed Sanofi 2015-06-30
NCT01948193 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth https://ClinicalTrials.gov/show/NCT01948193 Completed Sanofi 2014-12-31
NCT01933776 Study of the Tdap Combined Vaccine (ADACELâ„¢) as a Booster Dose in Healthy Adults and Children in China https://ClinicalTrials.gov/show/NCT01933776 Completed Sanofi 2013-11-30
NCT01926015 Immunogenicity and Safety of Concomitant Administration of RotaTeqâ„¢ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) https://ClinicalTrials.gov/show/NCT01926015 Completed Merck Sharp & Dohme Corp. 2014-06-06
NCT01917357 A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject https://ClinicalTrials.gov/show/NCT01917357 Completed Crucell Holland BV 2014-04-30
NCT01897402 Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01897402 Completed JN-International Medical Corporation 2014-05-31
NCT01896596 Hepatitis B Vaccination in Infants https://ClinicalTrials.gov/show/NCT01896596 Completed Public Health England 2017-04-30
NCT01878435 Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya https://ClinicalTrials.gov/show/NCT01878435 Completed Johns Hopkins Bloomberg School of Public Health 2016-02-29
NCT04398706 Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants https://ClinicalTrials.gov/show/NCT04398706 Recruiting Sanofi 2022-12-31
NCT01738477 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Boostrixâ„¢ Vaccine in Previously Boosted Young Adults https://ClinicalTrials.gov/show/NCT01738477 Completed GlaxoSmithKline 2014-04-02
NCT01711645 Tdap Vaccine in Post-Partum Women https://ClinicalTrials.gov/show/NCT01711645 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-08-28
NCT01689324 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents https://ClinicalTrials.gov/show/NCT01689324 Completed Sanofi 2012-11-30
NCT01659996 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age https://ClinicalTrials.gov/show/NCT01659996 Completed Sanofi 2014-11-30
NCT01629589 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents https://ClinicalTrials.gov/show/NCT01629589 Completed Sanofi 2013-03-31
NCT01577732 Safety of GSK Biologicals’ Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers https://ClinicalTrials.gov/show/NCT01577732 Completed GlaxoSmithKline 2013-04-09
NCT01546909 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE https://ClinicalTrials.gov/show/NCT01546909 Completed Sanofi 2012-12-31
NCT01529645 Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years https://ClinicalTrials.gov/show/NCT01529645 Completed Novartis 2012-07-31
NCT01519713 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects https://ClinicalTrials.gov/show/NCT01519713 Completed Sanofi 2012-09-30
NCT01491087 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China https://ClinicalTrials.gov/show/NCT01491087 Completed Sanofi 2012-07-31
NCT01470287 Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age https://ClinicalTrials.gov/show/NCT01470287 Completed Novartis 2012-04-30
NCT01457560 Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine https://ClinicalTrials.gov/show/NCT01457560 Completed GlaxoSmithKline 2001-04-30
NCT01457547 Comparison of Immunogenicity and Reactogenicity of INFANRIXâ„¢ HEXA and HEXAVACâ„¢ Vaccines as a Primary Vaccination Course https://ClinicalTrials.gov/show/NCT01457547 Completed GlaxoSmithKline 2005-05-31
NCT01457508 Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately https://ClinicalTrials.gov/show/NCT01457508 Completed GlaxoSmithKline 2000-03-31
NCT01457495 Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly https://ClinicalTrials.gov/show/NCT01457495 Completed GlaxoSmithKline 1999-09-30
NCT01453998 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744) https://ClinicalTrials.gov/show/NCT01453998 Completed GlaxoSmithKline 2012-11-12
NCT01449812 Immunogenicity and Safety Study of Booster Dose of GSK Biologicals’ IPV (Poliorixâ„¢) and DTPa/Hib (Infanrix+Hibâ„¢) Vaccine https://ClinicalTrials.gov/show/NCT01449812 Completed GlaxoSmithKline 2012-01-16
NCT01444781 Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexaâ„¢ and Prevenarâ„¢ in Healthy Infants https://ClinicalTrials.gov/show/NCT01444781 Completed Sanofi 2013-04-30
NCT01437423 Regulatory Post-Marketing Surveillance Study for TETRAXIMâ„¢ https://ClinicalTrials.gov/show/NCT01437423 Completed Sanofi 2015-11-30
NCT01439165 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose https://ClinicalTrials.gov/show/NCT01439165 Completed Sanofi 2015-12-31
NCT01362517 Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B https://ClinicalTrials.gov/show/NCT01362517 Completed Crucell Holland BV 2010-07-31
NCT01362322 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents https://ClinicalTrials.gov/show/NCT01362322 Completed GlaxoSmithKline 2012-09-03
NCT01358825 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ https://ClinicalTrials.gov/show/NCT01358825 Completed GlaxoSmithKline 2011-07-31
NCT01357720 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination https://ClinicalTrials.gov/show/NCT01357720 Completed Crucell Holland BV 2011-09-30
NCT01353703 Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals’ Infanrix Hexaâ„¢ (DTPa-HBV-IPV/Hib) Vaccine https://ClinicalTrials.gov/show/NCT01353703 Completed GlaxoSmithKline 2013-02-25
NCT01346293 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age https://ClinicalTrials.gov/show/NCT01346293 Completed Sanofi 2013-05-31
NCT01323959 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults https://ClinicalTrials.gov/show/NCT01323959 Completed GlaxoSmithKline 2012-03-01
NCT00452686 Study to Assess Safety & Immunogenicity of GSK Biologicals’ Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine https://ClinicalTrials.gov/show/NCT00452686 Completed GlaxoSmithKline NA
NCT04238975 A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults https://ClinicalTrials.gov/show/NCT04238975 Recruiting Green Cross Corporation 2021-02-28
NCT04177485 Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda https://ClinicalTrials.gov/show/NCT04177485 Completed Centers for Disease Control and Prevention 2017-12-04
NCT04099303 Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . https://ClinicalTrials.gov/show/NCT04099303 Recruiting CanSino Biologics Inc. 2020-12-20
NCT04075175 Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects https://ClinicalTrials.gov/show/NCT04075175 Completed MassBiologics 2019-10-07
NCT03998215 Diphtheria Vaccination in Adolescents With Inflammatory Bowel Disease https://ClinicalTrials.gov/show/NCT03998215 Completed Medical University of Warsaw 2015-01-01
NCT03950986 Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System https://ClinicalTrials.gov/show/NCT03950986 Completed Atlanta VA Medical Center 2019-05-30
NCT03931239 The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks https://ClinicalTrials.gov/show/NCT03931239 Completed Vabiotech 2018-06-30
NCT03891758 Confirmatory Study of BK1310 in Healthy Infants https://ClinicalTrials.gov/show/NCT03891758 Active, not recruiting Mitsubishi Tanabe Pharma Corporation 2019-09-18
NCT03552445 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine https://ClinicalTrials.gov/show/NCT03552445 Completed Korea University Guro Hospital 2016-04-30
NCT00835237 Evaluation of GlaxoSmithKline Biologicals’ Boostrix® Vaccine in Comparison With Decavacâ„¢ Vaccine. https://ClinicalTrials.gov/show/NCT00835237 Completed GlaxoSmithKline 2009-07-23
NCT01267058 Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT01267058 Completed GlaxoSmithKline 1998-02-28
NCT01262924 Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine https://ClinicalTrials.gov/show/NCT01262924 Completed GlaxoSmithKline 1998-12-31
NCT01249183 Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old https://ClinicalTrials.gov/show/NCT01249183 Completed Sanofi 2011-09-30
NCT01248884 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744) https://ClinicalTrials.gov/show/NCT01248884 Completed GlaxoSmithKline 2012-01-05
NCT01245049 Immunogenicity and Safety of GSK Biologicals’ Boostrix Polio Vaccine in 3 and 4-year-old Children https://ClinicalTrials.gov/show/NCT01245049 Completed GlaxoSmithKline 2012-03-27
NCT01214889 Study of PENTAXIMâ„¢ Vaccine Versus TETRAXIMâ„¢ Vaccine Given With ACTHIBâ„¢ Vaccine in South Korean Infants. https://ClinicalTrials.gov/show/NCT01214889 Completed Sanofi 2011-11-30
NCT01177722 A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenarâ„¢ and Rotarixâ„¢ in Healthy Latin American Infants https://ClinicalTrials.gov/show/NCT01177722 Completed Sanofi 2011-10-31
NCT01171989 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine Administered as a Booster Dose https://ClinicalTrials.gov/show/NCT01171989 Completed GlaxoSmithKline 2010-12-03
NCT01147900 Evaluation of Boostrixâ„¢10 Years After Previous Booster Vaccination https://ClinicalTrials.gov/show/NCT01147900 Completed GlaxoSmithKline 2012-05-08
NCT01137435 Post Marketing Surveillance for ADACELâ„¢ in South Korea https://ClinicalTrials.gov/show/NCT01137435 Completed Sanofi 2016-03-31
NCT01125527 Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children https://ClinicalTrials.gov/show/NCT01125527 Completed Novartis 2009-10-31
NCT01106092 Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT01106092 Completed GlaxoSmithKline 2010-09-02
NCT01090453 Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine in Healthy Infants https://ClinicalTrials.gov/show/NCT01090453 Completed GlaxoSmithKline 2011-10-11
NCT01086423 Immunogenicity and Safety Study of GSK Biologicals’ Infanrix-IPV+Hibâ„¢ Vaccine https://ClinicalTrials.gov/show/NCT01086423 Completed GlaxoSmithKline 2010-11-19
NCT01062477 A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants https://ClinicalTrials.gov/show/NCT01062477 Completed Sanofi 2011-09-30
NCT01044316 Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China https://ClinicalTrials.gov/show/NCT01044316 Completed Novartis 2010-07-31
NCT01040052 A Study to Assess the Safety of Adacel® Vaccine https://ClinicalTrials.gov/show/NCT01040052 Completed Sanofi 2010-02-28
NCT01033877 Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults https://ClinicalTrials.gov/show/NCT01033877 Completed Statens Serum Institut 2010-08-31
NCT01031303 Immunogenicity and Safety of TETRAXIMâ„¢ Given as a Booster Dose at 4 to 6 Years of Age https://ClinicalTrials.gov/show/NCT01031303 Completed Sanofi 2010-09-30
NCT00970307 Immunogenicity and Safety Study of GSK Biologicals’ GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age https://ClinicalTrials.gov/show/NCT00970307 Completed GlaxoSmithKline 2010-01-27
NCT00964028 Safety Study of GSK Biologicals’ DTPa-IPV/Hib (Infanrixâ„¢-IPV/Hib) https://ClinicalTrials.gov/show/NCT00964028 Completed GlaxoSmithKline 2010-04-12
NCT03870061 Evaluation of an Infant Immunization Encouragement Program in Nigeria https://ClinicalTrials.gov/show/NCT03870061 Completed GiveWell 2020-02-20
NCT00879827 Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants https://ClinicalTrials.gov/show/NCT00879827 Completed GlaxoSmithKline 2001-05-31
NCT00871117 Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years https://ClinicalTrials.gov/show/NCT00871117 Completed GlaxoSmithKline 2010-01-15
NCT00871000 Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. https://ClinicalTrials.gov/show/NCT00871000 Completed GlaxoSmithKline 2009-11-18
NCT03208101 A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults https://ClinicalTrials.gov/show/NCT03208101 Completed LG Chem 2017-09-06
NCT00831753 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants https://ClinicalTrials.gov/show/NCT00831753 Completed Sanofi 2009-05-31
NCT00831311 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants https://ClinicalTrials.gov/show/NCT00831311 Completed Sanofi 2005-11-30
NCT00802867 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ https://ClinicalTrials.gov/show/NCT00802867 Completed Sanofi 2005-06-30
NCT00777790 Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents https://ClinicalTrials.gov/show/NCT00777790 Completed Sanofi 2004-04-30
NCT00777257 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine https://ClinicalTrials.gov/show/NCT00777257 Completed Sanofi 2007-03-31
NCT00772928 Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacelâ„¢ https://ClinicalTrials.gov/show/NCT00772928 Completed Sanofi 2006-05-31
NCT00772070 Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine https://ClinicalTrials.gov/show/NCT00772070 Completed Sanofi 2003-08-31
NCT00771849 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children https://ClinicalTrials.gov/show/NCT00771849 Completed Sanofi 2004-03-31
NCT00753649 Immunogenicity and Safety of GSK Biologicals’ Infanrix Hexa in Infants https://ClinicalTrials.gov/show/NCT00753649 Completed GlaxoSmithKline 2013-03-12
NCT00715234 Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients https://ClinicalTrials.gov/show/NCT00715234 Completed University of Colorado, Denver 2009-12-31
NCT00712959 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose https://ClinicalTrials.gov/show/NCT00712959 Completed Sanofi 2009-09-30
NCT00707148 Pertussis Vaccine in Healthy Pregnant Women https://ClinicalTrials.gov/show/NCT00707148 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2012-05-31
NCT00696423 Immunogenicity and Safety of GSK Biologicals’ Infanrix/Hib in Children https://ClinicalTrials.gov/show/NCT00696423 Completed GlaxoSmithKline 2008-07-26
NCT00674908 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine https://ClinicalTrials.gov/show/NCT00674908 Completed Shantha Biotechnics Limited 2009-03-31
NCT00662870 Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine https://ClinicalTrials.gov/show/NCT00662870 Completed Sanofi 2004-01-31
NCT00654901 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexaâ„¢ https://ClinicalTrials.gov/show/NCT00654901 Completed Sanofi 2009-05-31
NCT00643916 Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age https://ClinicalTrials.gov/show/NCT00643916 Completed Sanofi 2006-03-31
NCT00635128 Safety and Immunogenicity of a Booster Dose of GSK Biological’s Boostrix-Polio Vaccine https://ClinicalTrials.gov/show/NCT00635128 Completed GlaxoSmithKline 2008-07-08
NCT00627458 Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio’s DTPa-HBV-IPV/Hib Vaccine https://ClinicalTrials.gov/show/NCT00627458 Completed GlaxoSmithKline 2008-08-18
NCT00619502 Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants https://ClinicalTrials.gov/show/NCT00619502 Completed Sanofi 2008-07-31
NCT00617812 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine https://ClinicalTrials.gov/show/NCT00617812 Completed Shantha Biotechnics Limited 2009-04-30
NCT00611559 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children https://ClinicalTrials.gov/show/NCT00611559 Completed GlaxoSmithKline 2008-06-25
NCT00610168 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. https://ClinicalTrials.gov/show/NCT00610168 Completed GlaxoSmithKline 2008-04-30
NCT00601835 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td https://ClinicalTrials.gov/show/NCT00601835 Completed Sanofi 2005-07-31
NCT00548171 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 https://ClinicalTrials.gov/show/NCT00548171 Completed GlaxoSmithKline 2008-04-30
NCT00534833 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hibâ„¢ https://ClinicalTrials.gov/show/NCT00534833 Completed Sanofi 2008-09-30
NCT00514709 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants https://ClinicalTrials.gov/show/NCT00514709 Completed Sanofi 2008-12-31
NCT00514059 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine https://ClinicalTrials.gov/show/NCT00514059 Completed Norwegian Institute of Public Health NA
NCT00473668 Non-inferiority of GSK Biologicals’ DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals’ DTPw-HBV/Hib https://ClinicalTrials.gov/show/NCT00473668 Completed GlaxoSmithKline 2008-01-30
NCT00467519 Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age https://ClinicalTrials.gov/show/NCT00467519 Completed Sanofi 2009-11-30
NCT00463437 Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines https://ClinicalTrials.gov/show/NCT00463437 Completed GlaxoSmithKline 2008-01-21
NCT00457249 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older https://ClinicalTrials.gov/show/NCT00457249 Completed Sanofi 2008-09-30
NCT00453570 Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months https://ClinicalTrials.gov/show/NCT00453570 Completed Sanofi 2008-12-31
NCT00447525 REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children https://ClinicalTrials.gov/show/NCT00447525 Completed Sanofi 2008-01-31
NCT00432042 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) https://ClinicalTrials.gov/show/NCT00432042 Completed Merck Sharp & Dohme Corp. 2008-03-27
NCT00412854 Study to Assess Safety & Immunogenicity of GSK Biologicals’ DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. https://ClinicalTrials.gov/show/NCT00412854 Completed GlaxoSmithKline 2007-06-01
NCT00406562 Study to Assess the Safety & Reactogenicity of GSK Biologicals’ dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. https://ClinicalTrials.gov/show/NCT00406562 Completed GlaxoSmithKline NA
NCT00404651 Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants https://ClinicalTrials.gov/show/NCT00404651 Completed Sanofi 2008-04-30
NCT00401531 Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants https://ClinicalTrials.gov/show/NCT00401531 Completed Sanofi 2007-11-30
NCT00379977 Study to Assess the Safety & Reactogenicity of GSK Biologicals’ DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age https://ClinicalTrials.gov/show/NCT00379977 Completed GlaxoSmithKline NA
NCT00376779 Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age https://ClinicalTrials.gov/show/NCT00376779 Completed GlaxoSmithKline 2007-05-31
NCT00362427 Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® https://ClinicalTrials.gov/show/NCT00362427 Completed Sanofi 2009-02-28
NCT00362336 Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV https://ClinicalTrials.gov/show/NCT00362336 Completed Sanofi 2008-05-31
NCT00355121 Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® https://ClinicalTrials.gov/show/NCT00355121 Completed Sanofi 2009-06-30
NCT00352963 Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). https://ClinicalTrials.gov/show/NCT00352963 Completed GlaxoSmithKline NA
NCT00348881 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hibâ„¢, Concomitantly With OPV in Healthy Infants https://ClinicalTrials.gov/show/NCT00348881 Completed Sanofi 2007-10-31
NCT00347958 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine https://ClinicalTrials.gov/show/NCT00347958 Completed Sanofi 2008-02-29
NCT00346073 Safety and Immunogenicity of GSK’s Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years https://ClinicalTrials.gov/show/NCT00346073 Completed GlaxoSmithKline 2007-03-01
NCT00343889 Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hibâ„¢, Both Given Concomitantly With Oral Polio Vaccine https://ClinicalTrials.gov/show/NCT00343889 Completed Sanofi 2007-11-30
NCT00343421 Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers https://ClinicalTrials.gov/show/NCT00343421 Completed Sanofi 2008-06-30
NCT00337428 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) https://ClinicalTrials.gov/show/NCT00337428 Completed Merck Sharp & Dohme Corp. 2007-05-31
NCT00332566 Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib https://ClinicalTrials.gov/show/NCT00332566 Completed GlaxoSmithKline 2006-10-31
NCT00325156 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants https://ClinicalTrials.gov/show/NCT00325156 Completed GlaxoSmithKline 2007-08-23
NCT00325143 Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine https://ClinicalTrials.gov/show/NCT00325143 Completed GlaxoSmithKline 2007-02-01
NCT00325130 Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) https://ClinicalTrials.gov/show/NCT00325130 Completed Merck Sharp & Dohme Corp. 2007-04-30
NCT00320463 Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants https://ClinicalTrials.gov/show/NCT00320463 Completed GlaxoSmithKline NA
NCT00319852 Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV https://ClinicalTrials.gov/show/NCT00319852 Completed Sanofi 2008-04-30
NCT00317187 Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. https://ClinicalTrials.gov/show/NCT00317187 Completed GlaxoSmithKline 2005-01-16
NCT00317174 A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. https://ClinicalTrials.gov/show/NCT00317174 Completed GlaxoSmithKline NA
NCT00317161 Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. https://ClinicalTrials.gov/show/NCT00317161 Completed GlaxoSmithKline 2005-04-30
NCT00317135 Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. https://ClinicalTrials.gov/show/NCT00317135 Completed GlaxoSmithKline 2004-10-23
NCT00317122 Assess the Immune Response Following Primary Vaccination With GSK Biologicals’ Tritanrixâ„¢-HepB/Hib-MenAC vs Tritanrixâ„¢-HepB/Hiberixâ„¢ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth https://ClinicalTrials.gov/show/NCT00317122 Completed GlaxoSmithKline 2005-07-31
NCT00316147 Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules https://ClinicalTrials.gov/show/NCT00316147 Completed GlaxoSmithKline NA
NCT00315055 Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule https://ClinicalTrials.gov/show/NCT00315055 Completed Sanofi 2007-07-31
NCT00313911 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hibâ„¢ and OPV Given at Age 2, 4, and 6 Months. https://ClinicalTrials.gov/show/NCT00313911 Completed Sanofi 2008-01-31
NCT00307567 Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 https://ClinicalTrials.gov/show/NCT00307567 Completed GlaxoSmithKline NA
NCT00304265 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine https://ClinicalTrials.gov/show/NCT00304265 Completed Sanofi 2006-10-31
NCT00303316 Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIMâ„¢ at 18 Months in Healthy Argentinean Infants https://ClinicalTrials.gov/show/NCT00303316 Completed Sanofi 2007-04-30
NCT00291967 Assess Immune Response Following Primary Vaccination With Tritanrixâ„¢-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants https://ClinicalTrials.gov/show/NCT00291967 Completed GlaxoSmithKline NA
NCT00290342 Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants https://ClinicalTrials.gov/show/NCT00290342 Completed GlaxoSmithKline 2007-01-01
NCT00290303 Assess if Immune Response of GSK Biologicals’ Tritanrixâ„¢-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrixâ„¢-HepB/Hiberixâ„¢ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants https://ClinicalTrials.gov/show/NCT00290303 Completed GlaxoSmithKline 2005-03-31
NCT00287092 Comparison of Safety and Immunogenicity of Pediacelâ„¢ and Infanrixâ„¢ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants https://ClinicalTrials.gov/show/NCT00287092 Completed Sanofi 2007-05-31
NCT00282295 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease https://ClinicalTrials.gov/show/NCT00282295 Completed GlaxoSmithKline 2006-08-08
NCT00263692 Comparison of GSK Biologicals’ DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety https://ClinicalTrials.gov/show/NCT00263692 Completed GlaxoSmithKline 2004-09-30
NCT00263679 Assessment of GSK Biologicals’ Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. https://ClinicalTrials.gov/show/NCT00263679 Completed GlaxoSmithKline 2004-05-31
NCT00259337 Immunogenicity and Safety of Pentaximâ„¢ in an Indian Population https://ClinicalTrials.gov/show/NCT00259337 Completed Sanofi 2008-04-30
NCT00258908 Immunogenicity and Safety of ADACELâ„¢ as Fifth Dose in Taiwan https://ClinicalTrials.gov/show/NCT00258908 Completed Sanofi 2006-08-31
NCT00258895 Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® https://ClinicalTrials.gov/show/NCT00258895 Completed Sanofi 2006-12-31
NCT00255047 Safety and Immune Response of Different Pediatric Combination Vaccines. https://ClinicalTrials.gov/show/NCT00255047 Completed Sanofi 2008-07-31
NCT00255021 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand https://ClinicalTrials.gov/show/NCT00255021 Completed Sanofi 2007-09-30
NCT00254969 Immunogenicity and Safety of Pentaxim in South African Infants https://ClinicalTrials.gov/show/NCT00254969 Completed Sanofi 2008-05-31
NCT00254917 Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines https://ClinicalTrials.gov/show/NCT00254917 Completed Sanofi 2006-02-28
NCT00244673 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination https://ClinicalTrials.gov/show/NCT00244673 Completed Bandim Health Project 2011-12-31
NCT00228917 Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children https://ClinicalTrials.gov/show/NCT00228917 Completed GlaxoSmithKline 2006-01-20
NCT00197275 Lot-to-lot Consistency of Tritanrixâ„¢-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrixâ„¢-HepB/Hiberixâ„¢ in Infants https://ClinicalTrials.gov/show/NCT00197275 Completed GlaxoSmithKline NA
NCT02477995 Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants https://ClinicalTrials.gov/show/NCT02477995 Completed Jiangsu Province Centers for Disease Control and Prevention 2014-05-31
NCT00169442 Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants https://ClinicalTrials.gov/show/NCT00169442 Completed GlaxoSmithKline 2006-03-01
NCT00168545 Immunology of Non-specific Effects of Vaccine https://ClinicalTrials.gov/show/NCT00168545 Completed Bandim Health Project NA
NCT00164411 Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine https://ClinicalTrials.gov/show/NCT00164411 Completed Centers for Disease Control and Prevention NA
NCT00158808 Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths https://ClinicalTrials.gov/show/NCT00158808 Completed GlaxoSmithKline 2005-04-30
NCT00148941 Immune Response and Safety Comparison of 3 Lots of GSK Biologicals’ DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines https://ClinicalTrials.gov/show/NCT00148941 Completed GlaxoSmithKline 2006-11-01
NCT00136604 Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m https://ClinicalTrials.gov/show/NCT00136604 Completed GlaxoSmithKline 2006-04-23
NCT00133445 Pentavalent DTaP-Hep B-IPV https://ClinicalTrials.gov/show/NCT00133445 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2006-08-31
NCT00109330 A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine https://ClinicalTrials.gov/show/NCT00109330 Completed GlaxoSmithKline 2004-04-30
NCT00092469 Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) https://ClinicalTrials.gov/show/NCT00092469 Completed Merck Sharp & Dohme Corp. 2003-08-31
NCT00797511 Immunogenicity and Safety of Adacel Polio Vaccine https://ClinicalTrials.gov/show/NCT00797511 Completed Sanofi 2009-04-30
NCT00319553 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® https://ClinicalTrials.gov/show/NCT00319553 Completed Sanofi 2008-10-31
NCT00489970 Persistence Study of GSK Biologicals’ Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 https://ClinicalTrials.gov/show/NCT00489970 Completed GlaxoSmithKline 2011-09-01
NCT00385255 Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults https://ClinicalTrials.gov/show/NCT00385255 Completed GlaxoSmithKline 2007-02-28

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. https://ClinicalTrials.gov/show/NCT02757950 Completed GlaxoSmithKline 2017-05-31
NCT02569879 Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia. https://ClinicalTrials.gov/show/NCT02569879 Completed GlaxoSmithKline 2018-04-14
NCT02447978 Duration of Protection: GSK DTaP Vaccines https://ClinicalTrials.gov/show/NCT02447978 Completed GlaxoSmithKline 2015-06-30
NCT01929291 Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea https://ClinicalTrials.gov/show/NCT01929291 Completed GlaxoSmithKline 2016-01-11
NCT01890850 Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants https://ClinicalTrials.gov/show/NCT01890850 Completed GlaxoSmithKline 2013-11-30
NCT01583049 Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children https://ClinicalTrials.gov/show/NCT01583049 Completed Sanofi 2012-08-31
NCT01568060 Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea https://ClinicalTrials.gov/show/NCT01568060 Completed GlaxoSmithKline 2015-12-31
NCT04061382 Sero-epidemiological Survey of England in 2019/2020 https://ClinicalTrials.gov/show/NCT04061382 Recruiting University of Oxford 2020-12-31
NCT01105559 Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine https://ClinicalTrials.gov/show/NCT01105559 Completed Sanofi 2011-11-30
NCT00908115 Post Market Surveillance for Infanrixâ„¢ https://ClinicalTrials.gov/show/NCT00908115 Completed GlaxoSmithKline 2008-06-23
NCT00855855 Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease https://ClinicalTrials.gov/show/NCT00855855 Active, not recruiting Sanofi 2020-01-31
NCT00804284 Database Surveillance Safety Study of PENTACEL® Vaccine https://ClinicalTrials.gov/show/NCT00804284 Completed Sanofi 2014-08-31
NCT00772369 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children https://ClinicalTrials.gov/show/NCT00772369 Completed Sanofi 2004-04-30
NCT00524732 Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age https://ClinicalTrials.gov/show/NCT00524732 Completed Sanofi 2004-12-31
NCT00297856 Post-marketing Safety Study of GSK Biologicals’ Boostrix® Vaccine https://ClinicalTrials.gov/show/NCT00297856 Completed GlaxoSmithKline 2006-12-31
NCT00146835 Post-marketing Safety Study of GSK Biological’s Pediarixâ„¢ Vaccine https://ClinicalTrials.gov/show/NCT00146835 Completed GlaxoSmithKline 2006-06-30
NCT00138268 Pilot Study Freeze and Transport Immune Cells https://ClinicalTrials.gov/show/NCT00138268 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04082299 Immune Response followingTdap Vaccine in Pregnancy https://ClinicalTrials.gov/show/NCT04082299 Recruiting Hillel Yaffe Medical Center 2022-09-30